Drugs / CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Cell therapy targets CD19 via depletion
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02146924 Comparator | Oct 2014 → Jul 2026 overdue | B-cell acute lymphoblastic leukemia | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02146924 ↗ |
| Action | Deplete | “kill cancer cells” NCT02146924 ↗ |
| Modality | Cell therapy | “adoptive therapy using ex vivo expanded memory T cells that are enriched and genetically-modified” NCT02146924 ↗ |
| Route | Intravenous | “Given IV” NCT02146924 ↗ |
| Target | CD19 | “CD19-specific, hinge optimized, CD28-costimulatory chimeric antigen receptor (CAR)” NCT02146924 ↗ |